CPHI

China Pharma Holdings, Inc. [CPHI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CPHI Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

CPHI has more than 2 years of cash runway (28 months)

Earnings are expected to fall -100% next year

Does not have any significance market cap ($5.47M)

Profit margins (-0.61%) are lower than the previous year (-0.44%)

In the News

CPHI Financial details

Company Rating

Neutral

Market Cap

5.47M

Income

-4.6M

Revenue

7.01M

Book val./share

0.7

Cash/share

0.14

Dividend

Dividend %

Employees

234

Optionable

Shortable

Yes

Earnings

16 May 2024

P/E

-0.28

Forward P/E

PEG

0.03

P/S

0.42

P/B

0.21

P/C

2.34

P/FCF

Quick Ratio

0.25

Current Ratio

0.82

Debt / Equity

0.62

LT Debt / Equity

0.19

EPS (TTM)

-1.94

EPS next Y

EPS next Q

EPS this Y

-90.64%

EPS next Y

EPS next 5Y

EPS last 5Y

-48.08%

Revenue last 5Y

-8.49%

Revenue Q/Q

19.2%

EPS Q/Q

-58.62%

SMA20

-5.41%

SMA50

-23.91%

SMA100

-25.53%

Inst Own

Inst Trans

ROA

-31%

ROE

-97%

ROC

-0.17%

Gross Margin

-2%

Oper. Margin

-18%

Profit Margin

-61%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.32-2.7

52W High

52W Low

RSI

41.7

Rel Volume

1.72

Avg Volume

368.84K

Volume

634.22K

Perf Week

-13.76%

Perf Month

-8.21%

Perf Quarter

-42.66%

Perf Half Y

-52.81%

Beta

0.913

Volatility

0.02%, 0.02%

Prev Close

-2.53%

Price

0.3277

Change

-2.47%

CPHI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	12.53	12.45	10.45	7.71	2.07
Net income per share	-24.12	-3.62	-4.27	-9.72	-0.91
Operating cash flow per share	0.7	-0.05	-0.27	-0.39	-0.21
Free cash flow per share	0.54	-1.04	-0.75	-0.77	-0.21
Cash per share	1.29	1.16	5.37	1.94	0.44
Book value per share	10.6	9.17	6.52	4.08	2.2
Tangible book value per share	9.9	8.47	5.88	1.98	1.12
Share holders equity per share	10.6	9.17	6.52	4.08	2.2
Interest debt per share	5.59	8.85	14.12	7.93	1.46
Market cap	10.32M	19.45M	22.26M	5.05M	2.05M
Enterprise value	13.79M	25.92M	29.89M	11.77M	5.26M
P/E ratio	-0.49	-6.15	-5.65	-0.49	-0.66
Price to sales ratio	0.94	1.79	2.31	0.62	0.29
POCF ratio	16.96	-460.18	-89.11	-12.32	-2.93
PFCF ratio	21.85	-21.38	-32.36	-6.22	-2.88
P/B Ratio	1.12	2.43	3.7	1.18	0.27
PTB ratio	1.12	2.43	3.7	1.18	0.27
EV to sales	1.26	2.39	3.1	1.45	0.75
Enterprise value over EBITDA	-31.84	116.73	-1.2K	-13.88	2.87K
EV to operating cash flow	22.68	-613.29	-119.64	-28.75	-7.51
EV to free cash flow	29.21	-28.49	-43.45	-14.51	-7.39
Earnings yield	-2.04	-0.16	-0.18	-2.03	-1.5
Free cash flow yield	0.05	-0.05	-0.03	-0.16	-0.35
Debt to equity	0.49	0.93	2.08	2.04	0.62
Debt to assets	0.2	0.35	0.55	0.49	0.28
Net debt to EBITDA	-8.02	29.14	-306.76	-7.93	1.75K
Current ratio	0.56	0.47	0.86	0.47	0.88
Interest coverage	-10.54	-8.35	-5.75	8.37	-8.25
Income quality	-0.03	0.01	0.07	0.1	0.23
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.21	0.17	0.17	0.23	0.21
Research and developement to revenue	0.02	0.03	0.03	0.02	0.03
Intangibles to total assets	0.03	0.03	0.03	0.12	0.22
Capex to operating cash flow	-0.22	20.52	1.75	0.98	0.02
Capex to revenue	-0.01	-0.08	-0.05	-0.05	0
Capex to depreciation	-0.05	-0.32	-0.14	-0.15	0
Stock based compensation to revenue	0	0	0	0.01	0
Graham number	75.84	27.35	25.04	29.88	6.72
ROIC	-0.25	-0.17	-0.19	-0.7	-0.23
Return on tangible assets	-0.97	-0.15	-0.18	-0.66	-0.24
Graham Net	-10.94	-11.25	-10.17	-9.16	-1.53
Working capital	-4.47M	-6.08M	-1.42M	-6.77M	-823.73K
Tangible asset value	8.63M	7.39M	5.43M	2.08M	3.8M
Net current asset value	-7.42M	-7.79M	-7.54M	-7.53M	-3.02M
Invested capital	0.49	0.93	2.08	2.04	0.62
Average receivables	917.69K	655.53K	709.34K	649.93K	563.42K
Average payables	1.21M	1.3M	1.08M	796.92K	816.75K
Average inventory	4.32M	3.65M	3.52M	3.14M	3.34M
Days sales outstanding	24.32	19.59	31.62	20.92	34.48
Days payables outstanding	52.82	50.56	36.4	28.32	46.93
Days of inventory on hand	138.74	151.72	131.18	125.14	181.36
Receivables turnover	15.01	18.63	11.54	17.45	10.58
Payables turnover	6.91	7.22	10.03	12.89	7.78
Inventory turnover	2.63	2.41	2.78	2.92	2.01
ROE	-2.28	-0.39	-0.65	-2.38	-0.41
Capex per share	-0.16	-0.99	-0.47	-0.38	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.3	1.21	0.55	0.68	0.2
Net income per share	-1.06	-1.23	-0.3	-0.29	-0.12
Operating cash flow per share	0.46	-0.91	-0.11	0.38	0
Free cash flow per share	0.34	34.64K	-0.11	0.38	0
Cash per share	1.61	0.74	0.5	0.52	0.14
Book value per share	3.37	2.89	2.19	2.31	0.7
Tangible book value per share	1.63	1.51	1.15	1.54	0.36
Share holders equity per share	3.37	2.89	2.19	2.31	0.7
Interest debt per share	6.81	5.31	4	2.02	0.44
Market cap	6.1M	3.15M	3.39M	1.96M	6.43M
Enterprise value	12.83M	10.64M	10.28M	5.98M	9.64M
P/E ratio	-1.13	-0.4	-1.43	-0.63	-1.3
Price to sales ratio	2.09	1.61	3.09	1.08	2.99
POCF ratio	10.44	-2.15	-15.67	1.94	-287.98
PFCF ratio	14.03	0	-15.67	1.94	-239.43
P/B Ratio	1.42	0.67	0.78	0.32	0.86
PTB ratio	1.42	0.67	0.78	0.32	0.86
EV to sales	4.39	5.43	9.36	3.32	4.48
Enterprise value over EBITDA	-24.23	37.66	42.21	-8.38	-19.73
EV to operating cash flow	21.95	-7.24	-47.49	5.94	-431.79
EV to free cash flow	29.49	0	-47.49	5.94	-358.99
Earnings yield	-0.22	-0.63	-0.17	-0.4	-0.19
Free cash flow yield	0.07	17.76K	-0.06	0.51	0
Debt to equity	2.04	1.85	1.79	0.88	0.62
Debt to assets	0.49	0.5	0.5	0.35	0.28
Net debt to EBITDA	-12.7	26.5	28.29	-5.64	-6.57
Current ratio	0.47	0.51	0.52	0.82	0.88
Interest coverage	12.39	-12.14	-3.31	10.77	-23.57
Income quality	-0.46	3.08	0.36	-1.3	0.02
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.28	0.21	0.1	0.14	0.32
Research and developement to revenue	0.01	0.01	0.02	0.03	0.07
Intangibles to total assets	0.12	0.13	0.13	0.13	0.22
Capex to operating cash flow	-0.26	-38.12K	0	0	0.2
Capex to revenue	-0.05	28.55K	0	0	0
Capex to depreciation	-0.23	82.31K	0	0	-0.01
Stock based compensation to revenue	0.03	0	0	0	0
Graham number	8.97	8.96	3.84	3.91	1.35
ROIC	-0.1	0.3	-0.05	-0.01	-0.1
Return on tangible assets	-0.09	-0.13	-0.04	-0.06	-0.1
Graham Net	-7.57	-5.62	-4.07	-2.15	-0.49
Working capital	-6.77M	-5.84M	-5.02M	-1.25M	-823.73K
Tangible asset value	2.08M	2.43M	2.28M	4.08M	3.8M
Net current asset value	-7.53M	-6.61M	-5.82M	-3.43M	-3.02M
Invested capital	2.04	1.85	1.79	0.88	0.62
Average receivables	500.7K	577.8K	569.28K	422.28K	529.77K
Average payables	551.35K	758K	631.5K	622.69K	898.86K
Average inventory	2.92M	3.35M	3.84M	3.84M	3.75M
Days sales outstanding	14.31	31.73	36.68	19.82	27.73
Days payables outstanding	20.86	42.87	29.95	36.74	37.96
Days of inventory on hand	92.17	189.88	283.02	166.47	146.7
Receivables turnover	6.29	2.84	2.45	4.54	3.25
Payables turnover	4.31	2.1	3.01	2.45	2.37
Inventory turnover	0.98	0.47	0.32	0.54	0.61
ROE	-0.31	-0.43	-0.14	-0.13	-0.17
Capex per share	-0.12	34.64K	0	0	0

CPHI Frequently Asked Questions

What is China Pharma Holdings, Inc. stock symbol ?

China Pharma Holdings, Inc. is a CN stock and trading under the symbol CPHI

What is China Pharma Holdings, Inc. stock quote today ?

China Pharma Holdings, Inc. stock price is $0.3277 today.

Is China Pharma Holdings, Inc. stock public?

Yes, China Pharma Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 368.84K
Market Capitalization 5.47M
Employee 234
CEO Ms. Zhilin Li
Headquarters Haikou,CN
IPO Date 2002-04-17
Website https://www.chinapharmaholdings.com

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.